Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer

• Danny Lavigne, MD,
• Lucas Sideris, MD,
• Lara de Guerke, MD,
• Eve-Lyne Marchand, MD,
• Suzanne Fortin, MD,
• Pierre Dubé, MD,
• Peter Vavassis, MD,
• Marie-Hélène Auclair, MD,
• Michael Yassa, MD

Affiliations

Danny Lavigne, MD

Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada; Corresponding author: Danny Lavigne, MD

Lucas Sideris, MD

Department of Surgery, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada

Lara de Guerke, MD

Department of Gynecology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada

Eve-Lyne Marchand, MD

Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada

Suzanne Fortin, MD

Department of Gynecology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada

Pierre Dubé, MD

Department of Surgery, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada

Peter Vavassis, MD

Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada

Marie-Hélène Auclair, MD

Department of Gynecology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada

Michael Yassa, MD

Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada